Embryonic stem cell therapy of heart failure in genetic cardiomyopathy

Stem Cells

Volumn 26, Issue 10, 2008, Pages 2644-2653

  Yamada, Satsuki ^a   Nelson, Timothy J ^a   Crespo Diaz, Ruben J ^a   Perez Terzic, Carmen ^a,b   Liu, Xiao Ke ^a   Miki, Takashi ^c   Seino, Susumu ^d   Behfar, Atta ^a   Terzic, Andre ^a,b  

^a Departments of Medicine Molecular Pharmacology and Experimental Therapeutics and Medical Genetics   (Japan)

^b MAYO CLINIC   (United States)

^c CHIBA UNIVERSITY   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ABCC9; ATP sensitive K+ channels; Dilated cardiomyopathy; Genetics; KCNJ11; Kir6.2

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BETA GALACTOSIDASE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CELL THERAPY; CELL TRANSPLANTATION; CONGENITAL HEART DISEASE; EMBRYONIC STEM CELL; EXERCISE TOLERANCE; GAP JUNCTION; HEART FAILURE; HEMODYNAMICS; HUMAN DILATED CARDIOMYOPATHY 10; LUNG CONGESTION; MOUSE; MUTATION; NONHUMAN; SARCOMERE; STRESS; TRANSGENE; TREADMILL EXERCISE;

ANIMALS; CARDIOMEGALY; CARDIOMYOPATHIES; EMBRYONIC STEM CELLS; GENETIC PREDISPOSITION TO DISEASE; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; KATP CHANNELS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIUM; STEM CELL TRANSPLANTATION; STRESS, PHYSIOLOGICAL; TISSUE THERAPY; TREATMENT OUTCOME; VENTRICULAR REMODELING; WOUND HEALING;

EID: 55049112094     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0187     Document Type: Article

References (66)

1. Towbin JA, Bowles NE. The failing heart. Nature 2002;415:227-233.
2. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 2005;6:185-216.
3. Chien KR. Stress pathways and heart failure. Cell 1999;98:555-558.
4. Ashrafian H, Watkins H. Cardiomyopathies: Therapeutics based on molecular phenotype. J Am Coll Cardiol 2007;49:1251-1264.
5. ATP channel gating. Nat Genet 2004;36:382-387.
6. ATP channel causes maladaptive remodeling and heart failure in hypertension. Hum Mol Genet 2006;15:2285-2297.
7. + channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol 2006;577:1053-1065.
8. Zingman LV, Hodgson DM, Bast PH et al. Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A 2002;99:13278-13283.
9. ATP channels. Mol Psychiatry 2003;8:253-254.
10. + channel knockout compromises the metabolic benefit of exercise training, resulting in cardiac deficits. Diabetes 2004;53(suppl 3):S169-S175.
11. ATP channels in health and disease. J Mol Cell Cardiol 2005;38:937-943.
12. ATP channels in transgenic mice expressing dominant negative Kir6 subunits. Am J Physiol Heart Circ Physiol 2006;291:H543-H551.
13. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: The scientific foundations of cardiac repair. J Clin Invest 2005;115:572-583.
14. Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. Nature 2006;441:1097-1099.
15. Schächinger V, Erbs S, Elsässer A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-1221.
16. Sánchez P, San Román JA, Villa A et al. Contemplating the bright future of stem cell therapy for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006;3(suppl 1):S138-S151.
17. Bartunek J, Vanderheyden M, Wijns W et al. Bone-marrow-derived cells for cardiac stem cell therapy: Safe or still under scrutiny? Nat Clin Pract Cardiovasc Med 2007;4(suppl 1):S100-S105.
18. Pouly J, Hagège AA, Vilquin JT et al. Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy? Circulation 2004;110:1626-1631.
19. Van Laake LW, Van Hoof D, Mummery CL. Cardiomyocytes derived from stem cells. Ann Med 2005;37:499-512.
20. Menasché P. The potential of embryonic stem cells to treat heart disease. Curr Opin Mol Ther 2005;7:293-299.
21. Kolossov E, Bostani T, Roell W et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med 2006;203:2315-2327.
22. Solter D. From teratocarcinomas to embryonic stem cells and beyond: A history of embryonic stem cell research. Nat Rev Genet 2006;7:319-327.
23. He JQ, Ma Y, Lee Y et al. Human embryonic stem cells develop into multiple types of cardiac myocytes: Action potential characterization. Circ Res 2003;93:32-39.
24. Chung S, Dzeja PP, Faustino RS et al. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med 2007;4(suppl 1):S60-S67.
25. Perez-Terzic C, Faustino RS, Boorsma BJ et al. Stem cells transform into a cardiac phenotype with remodeling of the nuclear transport machinery. Nat Clin Pract Cardiovasc Med 2007;4(suppl 1):S68-S76.
26. Hodgson DM, Behfar A, Zingman LV et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol 2004;287:H471-H479.
27. Ménard C, Hagège AA, Agbulut O et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: A preclinical study. Lancet 2005;366:1005-1012.
28. Behfar A, Hodgson DM, Zingman LV et al. Administration of allogenic stem cells dosed to secure cardiogenesis and sustained infarct repair. Ann NY Acad Sci 2005;1049:189-198.
29. Nelson TJ, Ge ZD, Van Orman J et al. Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells. Anat Rec A Discov Mol Cell Evol Biol 2006;288:1216-1224.
30. Singla DK, Hacker TA, Ma L et al. Transplantation of embryonic stem cells into the infarcted mouse heart: Formation of multiple cell types. J Mol Cell Cardiol 2006;40:195-200.
31. Behfar A, Zingman LV, Hodgson DM et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J 2002;16:1558-1566.
32. Behfar A, Perez-Terzic C, Faustino RS et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med 2007;204:405-420.
33. van Laake LW, Hassink R, Doevendans PA et al. Heart repair and stem cells. J Physiol 2006;577:467-478.
34. Fraidenraich D, Benezra R. Embryonic stem cells prevent developmental cardiac defects in mice. Nat Clin Pract Cardiovasc Med 2006; 3(suppl 1):S14-S17.
35. ATP channel-deficient mice. Proc Natl Acad Sci U S A 1998;95:10402-10406.
36. + channel, predisposes to catecholamine-induced ventricular dysrhythmia. Diabetes 2004;53(suppl 3):S165-S168.
37. ATP channel imparts fatal susceptibility to endotoxemia. FASEB J 2006;20:2271-2280.
38. Chien KR. Genomic circuits and the integrative biology of cardiac diseases. Nature 2000;407:227-232.
39. Opie LH, Commerford PJ, Gersh BJ. Controversies in ventricular remodeling. Lancet 2006;367:356-367.
40. Bell J. Predicting disease using genomics. Nature 2004;429:453-456.
41. Gersh BJ, Simari RD. Cardiac cell-repair therapy: Clinical issues. Nat Clin Pract Cardiovasc Med 2006;3(suppl 1):S105-S109.
42. Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodelling. Nature 2002;415:240-243.
43. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005;85:1373-1416.
44. Ott HC, Matthiesen TS, Brechtken J et al. The adult human heart as a source for stem cells: Repair strategies with embryonic-like progenitor cells. Nat Clin Pract Cardiovasc Med 2007;4(suppl 1):S27-S39.
45. Ellison GM, Torella D, Karakikes I et al. Myocyte death and renewal: Modern concepts of cardiac cellular homeostasis. Nat Clin Pract Cardiovasc Med 2007;4(suppl 1):S52-S59.
46. Kissel CK, Lehmann R, Assmus B et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007;49:2341-2349.
47. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008;102:1319-1330.
48. Perez-Terzic C, Behfar A, Méry A et al. Structural adaptation of the nuclear pore complex in stem cell-derived cardiomyocytes. Circ Res 2003;92:444-452.
49. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008;453:322-329.
50. Kehat I, Khimovich L, Caspi O et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004;10:1282-1289.
51. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development. Cell 2008;132:661-680.
52. Erdö F, Bührle C, Blunk J et al. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab 2003;23:780-785.
53. Drukker M, Katz G, Urvach A et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 2002;99:9864-9869.
54. Fändrich F, Lin X, Chai GX et al. Preimplantation-stage stem cells induce long-term allogenic graft acceptance without supplementary host conditioning. Nat Med 2002;8:171-178.
55. Lila N, Amrein C, Guillemain R et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002;105:1949-1954.
56. Koch CA, Geraldes P, Platt JL. Immunosuppression by embryonic stem cells. STEM CELLS 2008;26:89-98.
57. ATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med 2007;4:110-116.
58. ATP channel polymorphism is associated with left ventricular size in hypertensive individuals: A large-scale community-based study. Hum Genet 2008;123:665-667.
59. Arrell DK, Niederländer NJ, Perez-Terzic C et al. Pharmacoproteomics: Advancing the efficacy and safety of regenerative therapeutics. Clin Pharmacol Ther 2007;82:316-319.
60. Behfar A, Terzic A. Cardioprotective repair through stem cell-based cardiopoiesis. J Appl Physiol 2007;103:1438-1440.
61. Arrell DK, Niederländer NJ, Faustino RS et al. Cardioinductive network guiding stem cell differentiation revealed by proteomic cartography of TNFα-primed endodermal secretome. STEM CELLS 2008;26:387-400.
62. Faustino RS, Behfar A, Perez-Terzic C et al. Genomic chart guiding embryonic stem cell cardiopoiesis. Genome Biol 2008;9:R6.
63. + biomarkers select a cardiopoietic lineage from embryonic stem cells. STEM CELLS 2008;26:1464 -1473.
64. Chien KR. Regenerative medicine and human models of human disease. Nature 2008;452:302-305.
65. Waldman SA, Terzic A. Individualized medicine and the imperative of global health. Clin Pharmacol Ther 2007;82:479-483.
66. Waldman SA, Terzic A. Therapeutic targeting: A crucible for individualized medicine. Clin Pharmacol Ther 2008;83:651- 654.